Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions

Current Medical Research and Opinion

Volumn 20, Issue 11, 2004, Pages 1759-1767

  Akbulut, Mehmet ^a   Ozbay, Yilmaz ^a   Gundogdu, Ozlem ^a   Dagli, Necati ^a   Durukan, Polat ^a   Ilkay, Erdogan ^a   Arslan, Nadi ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Acute systemic inflammatory response; Percutaneous coronary intervention; Tirofiban

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; SODIUM CHLORIDE; TIROFIBAN; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFECT; FEMALE; FOLLOW UP; HEART MUSCLE NECROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; STABLE ANGINA PECTORIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; ANGINA PECTORIS; ANGIOPLASTY, BALLOON; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYOCARDIUM; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; TROPONIN; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 10044270840     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X4400     Document Type: Article

References (46)

1. Zheng H, Barragan P, Corcos T, et al. Clinical experience with a new biocompatible phosphorylcholine coated coronary stent. J Invasive Cardiol 1999;10:608-14
2. Ross R. Atherosclerosis an inflammatory disease. New Eng J Med 1999;340:115-26
3. Shah KP. Circulating markers of inflammation for vascular risk prediction. Circulation 2000;105:1758-9
4. Herity AH. Interleukin 6: a new message from heart. Heart 2000;84:9-10
5. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41:37-42
6. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-42
7. Collaborative overview of randomised trials of antiplatelet therapy - II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet trialist's collaboration. Br Med J 1994;308:159-68
8. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103-15
9. Steinhubl SR, Ellis SG, Walski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001;103:1403-9
10. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494-502
11. Lincoff AM, Kereiakes DJ, Macselli MA, et al. Abciximab suppresses the rise in level of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-7
12. King SB for the RESTORE Investigators. Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53
13. Cannon PC for the TACTICS - Thrombolysis In Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. New Engl J Med 2001;344:1879-87
14. Topol EL for the EPISTENT - Investigators. Randomized placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92
15. Judkins MP. Selective coronary arteriography: a percutaneous trans femoral technique. Radiology 1967;89:815
16. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR Trial). J Am Coll Cardiol 2002;40:662-8
17. Aukrust P, Waehre T, Damas JK, et al. Inflammatory role of platelets in acute coronary syndromes. Heart 2001;86:605-6
18. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-8
19. Serrano CV, Ramires JAF, Venturinelli M, et al. Coronary angioplasty results in leucocyte and platelet activation with adhesion molecule expression. J Am Coll Cardiol 1997;29:1276-83
20. Blum A, Sclarovsky S, Shohat B. T lymphocytes activation in stable angina pectoris and after percutaneous transluminal coronary angioplasty. Circulation 1995;91:20-2
21. Akira S, Hirano T, Taga T, et al. Biology of multifunctional cytokines: IL 6 and related molecules (IL-1 and TNF-α). FASEB J 1990;4:2860-7
22. Hojo Y, Ikeda U, Katsuki T, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000;84:83-7
23. Gottsauner-Wolf M, Zasmeta G, Hornykewycz M, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000;21:1152-8
24. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72
25. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary event. Circulation 1999;99:2079-84
26. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-9
27. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-7
28. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998;98:2370-6
29. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis: Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to Standard treatment trial. CAPTURE Investigators. J Am Coll Cardiol 2000;35:1535-42
30. Chan AW, Moliterno DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival. J Am Coll Cardiol 2003;42:1188-95
31. Januzzi JL, Hahn SS, Chae CU, et al. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. Am J Cardiol 2000;86:713-7
32. Topol EJ, Moliterno DJ, Hermann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ishemic events with percutaneous coronary revascularization. New Engl J Med 2001;344:1888-94
33. Bonz AW, Lengenfelder B, Jacobs M, et al. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J 2003;145:693-9
34. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein in patients with unstable angina undergoing coronary stent implantation. Am J Cardiol 2000;85:92-5
35. Tam SH, Sassoli PM, Jordan RE, et al. Abciximab demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and avβ3 integrins. Circulation 1998;98:1085-91
36. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and block adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-35
37. Moliterno DJ, Yakubov SJ, D'Balliste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002;360:355-60
38. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:1740-45
39. Herkowitz A, Choi S, Ansari AA, et al. Cytokine mRNA expression in post-ischemic/reperfused mycardium. Am J Pathol 1995;146:419-28
40. Neumann FJ, Ott I, Gawatz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-55
41. Gurevitch J, Frolkis I, Yuhas Y, et al. Anti-tumor necrosis factor alpha improves myocardial recovery after ischemia and reperfusion. J Am Coll Cardiol 1997;30:1554-61
42. Li D, Zhao L, Liu M, et al. Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. Am Heart J 1999;137:1145-52
43. Kao K, Matsubara T, Lida K, et al. Elevated levels of proinflammatury cytokines in coronary artery thrombi. Int J Cardiol 1999;70:267-73
44. Hanson GK, Jonason L, Seifert PS, et al. Immune mechanism in atherosclerosis. Atherosclerosis 1989;9:567-78
45. Botaille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 1992;35:982-4
46. Merino A, Artaiz M, Vidal B, et al. Eptifibatide blocks the increase in C-reactive protein concentrations by coronary angioplasty. Circulation 2001;104:11-56